• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Carter Robert B was granted 1,203 shares, increasing direct ownership by 81% to 2,685 units (SEC Form 4)

    5/19/25 4:24:41 PM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    CARTER ROBERT B

    (Last) (First) (Middle)
    500 PLAZA DRIVE

    (Street)
    SECAUCUS NJ 07094

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    QUEST DIAGNOSTICS INC [ DGX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 05/15/2025 A 1,203 A $0 2,685 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents an award of restricted stock units.
    Remarks:
    Sean D. Mersten, Attorney-in-Fact for Robert B. Carter 05/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    7/10/2024$145.00 → $165.00Neutral → Buy
    Citigroup
    More analyst ratings

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

      Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

      4/2/25 8:51:11 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics downgraded by Citigroup with a new price target

      Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

      3/4/25 7:20:57 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously

      1/6/25 7:49:06 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

      Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

      1/17/24 8:58:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

      SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

      3/3/23 4:30:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quotient Limited Announces Appointment of Chief Financial Officer

      JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

      10/12/21 8:45:00 AM ET
      $DGX
      $QTNT
      Medical Specialities
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $DGX
    Financials

    Live finance-specific insights

    See more
    • Quest Diagnostics Declares Quarterly Cash Dividend

      SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti

      5/14/25 6:17:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

      First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

      4/22/25 6:43:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

      SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

      4/1/25 4:23:00 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Quest Diagnostics Incorporated

      SCHEDULE 13G - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      5/14/25 10:45:25 AM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Quest Diagnostics Incorporated

      144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      5/13/25 9:59:16 AM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Quest Diagnostics Incorporated

      10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      4/23/25 4:21:36 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals

      Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care SECAUCUS, N.J., May 20, 2025 /PRNewswire/ -- questhealth.com, the consumer-initiated testing platform from Quest Diagnostics (NYSE:DGX), one of the nation's leading providers of diagnostic information services, today revealed the results of its second "Know Your Health" survey, conducted online by The Harris Poll among nearly 2,100 U.S. adults. Findings revealed that most America

      5/20/25 8:52:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference

      SECAUCUS, N.J., May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m. Eastern Time. The presentation session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.

      5/16/25 1:11:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Declares Quarterly Cash Dividend

      SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti

      5/14/25 6:17:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/13/24 5:12:21 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      1/25/24 12:16:40 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/7/23 1:25:52 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Director Carter Robert B was granted 1,203 shares, increasing direct ownership by 81% to 2,685 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/19/25 4:24:41 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/19/25 4:24:09 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Director Gregg Vicky B was granted 1,203 shares, increasing direct ownership by 7% to 18,138 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/19/25 4:23:35 PM ET
      $DGX
      Medical Specialities
      Health Care